Home » Topics » Immuno-oncology, BioWorld Science

Immuno-oncology, BioWorld Science
RSS

First clinical trial of HER-2/neu-based vaccine in patients with breast and ovarian cancer

July 1, 2004

New phase II trial of MDX-070 in hormone refractory prostate cancer

June 29, 2004

SGN-15 and docetaxel combination promising in non-small cell lung cancer

June 29, 2004

Update on the antitumor efficacy of MDX-010

June 28, 2004

Panvac-VF enters phase III trial for pancreatic cancer

June 23, 2004

AMD-3100 improves the eligibility of MM patients for stem cell transplantation

June 23, 2004

FDA accepts Genmab IND for phase I/II study of HuMax-CD20 in CLL

June 22, 2004

Phase II data supports progression of Onyvax-P for advanced prostate cancer

June 22, 2004

Full enrollment in phase III Virulizin trial

June 21, 2004

PSMA-targeting immunotherapies presented at ASCO

June 21, 2004

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 5, 2025.
MicroRNAs in circulating extracellular vesicles as IPF biomarkers
BioWorld Science
MicroRNAs (miRNAs) are small noncoding RNAs gaining increasing attention due to their crucial role in gene expression regulation and influence in various cellular...
MJFF grant supports Bexorg’s translational biomarker work
BioWorld Science
Bexorg Inc. has been awarded a research grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) through the Targets to Therapies initiative to...
REST emerges as biomarker in ALS, knockdown improves ALS symptoms
BioWorld Science
About 10% of amyotrophic lateral sclerosis (ALS) cases result from inherited genetic mutations, with about 20% of them attributed to mutations in the gene...
Study identifies CAND1 as therapeutic target in hepatoblastoma
BioWorld Science
Hepatoblastoma is the most common liver cancer during childhood, with limited therapeutic options in aggressive or relapsed cases. NEDDylation is a...